Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to Lo Vasco et al.

Leukemia volume 20, page 523 (2006)Cite this article

In their letter,1 commenting to our paper,2 Lo Vasco et al. precise the prognostic data of the MDS patients included in their original paper3 on cryptic deletions of the inositide-specific phospholipase c β1 gene (PI-PLC β1). All the patients with MDS and a normal karyotype at diagnosis were at high risk as evaluated by clinical meanings (French-American-British classification (FAB), International Prognostic Scoring System (IPSS)). In our series,2 selection of the patients was done according to the unique criteria given by Lo Vasco et al. in their original paper,3 that is, the evidence of a normal karyotype at diagnosis. The IPSS score in our cases was low (12 patients), intermediate (10) or high (1). The discrepancies between the results of both studies probably can be explained by differences in the selection of the MDS populations. The data of Lo Vasco,1, 3 strictly related to high-risk IPSS categories, show that, respectively, 4/9 and 4/13 cases bear the PI-PLC β1 deletion. On the contrary, in our series where only one patient was at high risk, none of the 23 patients showed a cryptic deletion of band 20p12.3.2 Similar observations were recently done by Verburgh et al.4 who failed to detect a deletion of the PI-PLC β1 gene in a series of 33 MDS patients with normal karyotype, of which two belonged to the high-risk group as defined by the IPSS. In the same way, no deletion was observed in the 10 low-risk MDS patients reported in the comment of Lo Vasco et al.1 All these data indicate that the deletion of the PI-PLC β1 gene probably will not be detected in MDS patients with normal karyotype and low or intermediate IPSS risks. Conversely, in the high-risk group, the deletion could be frequent (about one-third of the reported cases till now) and associated with alterations of the signalling pathways and short survivals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lo Vasco VR, Follo MY, Cocco L . Reply to: Inositide-specific Phospholipase c β1 gene deletion is a rare event in myelodysplastic syndromes, by Christian Herens et al. Leukemia.

  2. Herens C, Ketelslegers O, Tassin F, Hanssen S, Bours V . Inositide-specific phospholipase c β1 gene deletion is a rare event in myelodysplastic syndromes. Leukemia.

  3. Lo Vasco VR, Calabrese G, Manzoli L, Palka G, Spadano A, Morizio E et al. Inositide-specific phospholipase c β1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukaemia. Leukemia 2004; 18: 1122–1126.

    Article  CAS  Google Scholar 

  4. Verburgh E, Verhoef G, Vandenberghe P, Hagemeijer A . Deletion of the inositide-specific phospholipase c β1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression. Leukemia 2005; 19: 2011–2013.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Genetics, CHU, University of Liège, Liège, Belgium

    C Herens, S Hansen & V Bours

  2. Department of Clinical Biology, CHR Citadelle, Liège, Belgium

    O Ketelslegers

  3. Department of Clinical Biology, Laboratory Haematology, CHU, University of Liège, Liège, Belgium

    F Tassin

Authors
  1. C Herens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Ketelslegers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Tassin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Bours
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Herens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herens, C., Ketelslegers, O., Tassin, F. et al. Reply to Lo Vasco et al.. Leukemia 20, 523 (2006). https://doi.org/10.1038/sj.leu.2404111

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404111

Search

Advanced search

Quick links